Skip to main content Accessibility help

Psychotropic prescribing in seriously violent men with schizophrenia or personality disorder in a UK high security hospital

  • Keir Stone-Brown (a1), Mahmood Naji (a2), Alex Francioni (a2), Kyle Myers (a2), Harsh Samarendra (a2), Haseeb Mushtaq-Chaudhry (a3), Stephen Heslop (a3), Samrat Sengupta (a3), Callum C. Ross (a3), Fintan Larkin (a3) and Mrigendra Das (a3)...



To analyze antipsychotic prescribing patterns in a UK high security hospital (HSH) that treats seriously violent men with either schizophrenia or personality disorder and examine how different groups consented to treatment and prescribing for metabolic conditions. We hypothesized that there would be high prevalence of antipsychotic polypharmacy, and high-dose antipsychotic and clozapine prescribing.


HSHs treat seriously violent, mentally disordered offenders, and the extant literature on prescribing patterns in forensic settings is sparse.


Prescribing and clinical data on all 189 patients in a UK HSH were collected from the hospital’s databases. Data were analyzed using SPSS.


The population was split into the following groups: schizophrenia spectrum disorder (SSD-only), personality disorder (PD-only), and comorbid schizophrenia spectrum disorder and PD. The majority (93.7%) of all patients were prescribed at least one antipsychotic, and (27.5%) were on clozapine. Polypharmacy was prevalent in 22.2% and high-dose antipsychotic in 27.5%. Patients on clozapine were more likely to be prescribed antidiabetic, statins, or antihypertensive medication. Patients in the PD-only group were more likely to be deemed to have the capacity to consent to treatment and be prescribed clozapine in contrast to the SSD-only group.


Rates of clozapine and high-dose antipsychotic prescribing were higher than in other psychiatric settings, while polypharmacy prescribing rates were lower. Higher clozapine prescribing rates may be a function of a treatment-resistant and aggressive population. A higher proportion of PD-only patients consented to treatment and received clozapine compared with in-house SSD-only as well as other psychiatric settings. Implications of the findings are discussed.


Corresponding author

*Address for correspondence: Mrigendra Das, Broadmoor Hospital, Crowthorne, Berkshire, RG45 7EG, UK. (Email:


Hide All
1. Brown, D, Larkin, F, Sengupta, S, Romero-Ureclay, JL, Ross, CC, Gupta, N, Das, M. Clozapine: an effective treatment for seriously violent and psychopathic men with antisocial personality disorder in a UK high-security hospital. CNS Spectr. 2014; 19(5): 391402.
2. Larkin, E, Murtagh, S, Jones, S. A preliminary study of violent incidents in a special hospital (Rampton). Br J Psychiatry. 1988; 153(2): 226231.
3. Gordon, H, Grubin, D. Psychiatric aspects of the assessment and treatment of sex offenders. Advances in Psychiatric Treatment. 2004; 10(1): 7380.
4. Rutherford, M, Duggan, S. Forensic mental health services: facts and figures on current provision. British Journal of Forensic Practice. 2008; 10(4): 410.
5. Blackburn, R, Logan, C, Donnelly, J, Renwick, S. Personality disorders, psychopathy and other mental disorders: co-morbidity among patients at English and Scottish high-security hospitals. Journal of Forensic Psychiatry & Psychology. 2003; 14(1): 111137.
6. Thomas, S, Leese, M, Dolan, M, et al. The individual needs of patients in high secure psychiatric hospitals in England. Journal of Forensic Psychiatry & Psychology. 2004; 15(2): 222243.
7. Stone, JH, Roberts, M, O’Grady, J, Taylor, AV, O’ Shea, K. Faulk’s Basic Forensic Psychiatry. Hoboken, NJ: Wiley; 1999.
8. Department of Health. Mental Health Act. London; 1983 rev. 2007; HMSO.
9. Hayhurst, K. Pennine Care NHS Trust Antipsychotic Prescribing Audit. Manchester, UK: The University of Manchester; 2006.
10. Harrington, M, Lelliott, P, Paton, C, Okocha, C, Duffett, R, Sensky, T. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatric Bulletin. 2002; 26(11): 414418.
11. Stahl, SM. “The metabolic syndrome”: psychopharmacologists should weigh the evidence for weighing the patient. J Clin Psychiatry. 2002; 63(12): 10941095.
12. Gupta, A, Dadheech, G, Yadav, D, Sharma, P, Gautam, S. Metabolic issues in schizophrenic patients receiving antipsychotic treatment. Indian J Clin Biochem. 2014; 29(2): 196201.
13. Ojala, K, Niskanen, L, Tiihonen, J, Paavola, P, Putkonen, A, Repo-Tiihonen, E. Characterization of metabolic syndrome among forensic psychiatric inpatients. Journal of Forensic Psychiatry & Psychology. 2008; 19(1): 3351.
14. Taylor, PJ, Leese, M, Williams, D, Butwell, M, Daly, R, Larkin, E. Mental disorder and violence: a special (high security) hospital study. Br J Psychiatry. 1998; 172(3): 218226.
15. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. London: BMJ Books & Pharmaceutical Press; 2015.
16. Stahl, SM. Antipsychotic polypharmacy: never say never, but never say always. Acta Psychiatr Scand. 2012; 125(5): 349351.
17. Stahl, SM. Emerging guidelines for the use of antipsychotic polypharmacy. Rev Psiquiatr Salud Ment. 2013; 6(3): 97100.
18. Stahl, SM. Antipsychotic polypharmacy: squandering precious resources? J Clin Psychiatry. 2002; 63(2): 9394.
19. Adams, CE, Fenton, MK, Quraishi, S, David, AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry. 2001; 179(4): 290299.
20. Barnes, TR, Shingleton-Smith, A, Paton, C. Antipsychotic long-acting injections: prescribing practice in the UK. Br J Psychiatry. 2009; 195(52): S37S42.
21. Gibbon, S, Silva, E, Kaler, R, et al. Risperidone long-acting injection (RLAI)—real world outcomes from the United Kingdom high-secure hospitals. The British Journal of Forensic Practice. 2011; 13(4): 264269.
22. Baruch, N, Das, M, Sharda, A, et al. An evaluation of the use of olanzapine pamoate depot injection in seriously violent men with schizophrenia in a UK high-security hospital. Ther Adv Psychopharmacol. 2014; 4(5): 186192.
23. Walsh, E, Leese, M, Taylor, P, et al. Psychosis in high-security and general psychiatric services Report from the UK700 and Special Hospitals’ Treatment Resistant Schizophrenia groups. Br J Psychiatry. 2002; 180(4): 351357.
24. Frogley, C, Taylor, D, Dickens, G, Picchioni, M. A systematic review of the evidence of clozapine’s anti-aggressive effects. Int J Neuropsychopharmacol. 2012; 15(9): 13511371.
25. Das, M, Barkataki, I, Kumari, V, Sharma, T. Neuroimaging violence in the mentally ill: what can it tell us? Hosp Med. 2002; 63(10): 604609.
26. Kumari, V, Das, M, Hodgins, S. Association between violent behaviour and impaired prepulse inhibition of the startle response in antisocial personality disorder and schizophrenia. Behav Brain Res. 2005; 158(1): 159166.
27. Kumari, V, Soni, W, Sharma, T. Normalization of information processing deficits in schizophrenia with clozapine. Am J Psychiatry. 1999; 156(7): 10461051.
28. Stahl, SM. Clozapine: is now the time for more clinicians to adopt this orphan? CNS Spectr. 2014; 19(4): 279281.
29. Raedler, TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry. 2010; 23(6): 574581.
30. Brown, D, Larkin, F, Sengupta, S, et al. Treatment of violent dissocial personality disorder patients with clozapine requires lower dose and therapeutic levels than in schizophrenia. Schizophrenia Research. 2014; 153(Suppl 1): S173.
31. Young, SL, Taylor, M, Lawrie, SM. “First do no harm”: a systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol. 2015; 29(4): 353362.
32. Hotham, JE, Simpson, PJ, Brooman-White, RS, et al. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. CNS Spectr. 2014; 19(5): 403410.
33. Genç, Y, Taner, E, Candansayar, S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: a single-blind randomized study. Adv Ther. 2007; 24(1): 113.
34. Cipriani, A, Boso, M, Barbui, C. Clozapine combined with different antipsychotic drugs for treatment resistant schizophrenia. Cochrane Database Syst Rev. 2009;(3): CD006324.
35. Suzuki, T, Uchida, H, Takeuchi, H, et al. Augmentation of atypical antipsychotics with valproic acid: an open‐label study for most difficult patients with schizophrenia. Hum Psychopharmacol. 2009; 24(8): 628638.
36. Ho, DK, Kottalgi, G, Ross, CC, Romero-Ulceray, J, Das, M. Treatment with triptorelin in mentally disordered sex offenders: experience from a maximum-security hospital. J Clin Psychopharmacol. 2012; 32(5): 739740.
37. Zachariah, E, Kumari, V, Galea, A, et al. Effects of oral procyclidine administration on cognitive functions in healthy subjects: implications for schizophrenia. J Clin Psychopharmacol. 2002; 22(2): 224226.
38. Ingenhoven, T, Lafay, P, Rinne, T, et al. Effectiveness of pharmacotherapy for severe personality disorders: meta-analyses of randomized controlled trials. J Clin Psychiatry. 2010; 71(1): 1425.
39. Stahl, SM, Morrissette, DA, Cummings, M, et al. California State Hospital Violence Assessment and Treatment (Cal-VAT) guidelines. CNS Spectr. 2014; 19(5): 449465.



Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed